This compound, also known as DNP-maleimide, is a commonly used reagent in chemical biology and biochemistry. It is a maleimide derivative that reacts with sulfhydryl groups (thiol groups) of cysteine residues in proteins. This property makes it useful for labeling proteins, modifying their activity, and studying protein-protein interactions. DNP-maleimide has been used to label and study the active site of various enzymes, including glutathione reductase, thioredoxin reductase, and protein disulfide isomerase. Its ability to modify cysteine residues allows researchers to investigate the role of these residues in protein function and to identify protein targets for drug discovery. DNP-maleimide is synthesized by reacting maleic anhydride with 4-dimethylamino-3,5-dinitroaniline in the presence of a catalyst, such as acetic acid. Its effects are primarily due to its reactivity towards thiols, leading to covalent modification of proteins.'
ID Source | ID |
---|---|
PubMed CID | 18990 |
CHEMBL ID | 1707040 |
SCHEMBL ID | 25445 |
MeSH ID | M0066357 |
Synonym |
---|
n-(4-dimethylamino-3,5-dinitrophenyl)maleimide |
1h-pyrrole-2, 1-[4-(dimethylamino)-3,5-dinitrophenyl]- |
3475-74-9 |
nsc90450 |
maleimide,5-dinitrophenyl]- |
mls002694988 , |
nsc-90450 |
maleimide, n-[4-(dimethylamino)-3,5-dinitrophenyl]- |
1h-pyrrole-2,5-dione, 1-[4-(dimethylamino)-3,5-dinitrophenyl]- |
n-(4-dimethylamino-3,5-dinitrophenyl)-maleimide |
nsc 90450 |
brn 0333082 |
1h-pyrrole-2,5-dione, 1-(4-(dimethylamino)-3,5-dinitrophenyl)- |
maleimide, n-(4-(dimethylamino)-3,5-dinitrophenyl)- |
ai3-62630 |
einecs 222-449-3 |
1-(4-(dimethylamino)-3,5-dinitrophenyl)-1h-pyrrole-2,5-dione |
smr001560901 |
1-[4-(dimethylamino)-3,5-dinitrophenyl]pyrrole-2,5-dione |
qpyauurpgvxhfk-uhfffaoysa- |
1-(4-dimethylamino-3,5-dinitrophenyl)pyrrole-2,5-dione |
inchi=1/c12h10n4o6/c1-13(2)12-8(15(19)20)5-7(6-9(12)16(21)22)14-10(17)3-4-11(14)18/h3-6h,1-2h3 |
HMS3092G11 |
ddpm cpd |
FT-0629221 |
SCHEMBL25445 |
AKOS024371039 |
CHEMBL1707040 |
cid_18990 |
1-[4-(dimethylamino)-3,5-dinitro-phenyl]pyrrole-2,5-dione |
bdbm80064 |
1-[4-(dimethylamino)-3,5-dinitro-phenyl]-3-pyrroline-2,5-quinone |
QPYAUURPGVXHFK-UHFFFAOYSA-N |
1-[4-(dimethylamino)-3,5-dinitrophenyl]-1h-pyrrole-2,5-dione # |
DTXSID30188305 |
1-[4-(dimethylamino)-3,5-dinitrophenyl]-1h-pyrrole-2,5-dione |
J-019742 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 8.9125 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 2.8184 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
WRN | Homo sapiens (human) | Potency | 35.4813 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
GLS protein | Homo sapiens (human) | Potency | 25.1189 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 1.2995 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 7.9433 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 15.8489 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 6.5131 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 2.9935 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 15.8489 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 14.6777 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 7.9433 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
Alpha-synuclein | Homo sapiens (human) | Potency | 5.6234 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.7943 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 (µMol) | 11.0900 | 2.3700 | 54.1398 | 100.0000 | AID588689 |
C-C chemokine receptor type 6 | Homo sapiens (human) | IC50 (µMol) | 37.0000 | 11.5000 | 14.3000 | 17.1000 | AID504728 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (33.33) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 2 (16.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.90) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |